Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Measuring and Predicting Response to Atomoxetine and Methylphenidate
NCT00183391Phase 4Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jul 2005
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of atomoxetine, methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Icahn School of Medicine at Mount Sinai. Started Jul 2005; status: completed.
02
Drugs
atomoxetinemethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00183391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00183391.